Common Stocks - 98.2%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 91.7%
|
|||
Biotechnology - 91.7%
|
|||
2seventy bio, Inc. (a)
|
103,752
|
1,625,794
|
|
4D Molecular Therapeutics, Inc. (a)
|
24,264
|
586,461
|
|
AbbVie, Inc.
|
3,617,903
|
583,133,604
|
|
Absci Corp. (a)(b)
|
997,800
|
2,494,500
|
|
ADC Therapeutics SA (a)(b)
|
635,838
|
2,327,167
|
|
Adicet Bio, Inc. (a)(b)
|
713,361
|
12,968,903
|
|
Adverum Biotechnologies, Inc. (a)(b)(c)
|
8,332,581
|
5,581,996
|
|
Aerovate Therapeutics, Inc. (a)(b)
|
77,051
|
1,451,641
|
|
Aldeyra Therapeutics, Inc. (a)(b)
|
961,337
|
5,383,487
|
|
Alector, Inc. (a)
|
914,318
|
7,762,560
|
|
Alkermes PLC (a)
|
687,536
|
17,037,142
|
|
Allena Pharmaceuticals, Inc. (a)
|
93,683
|
1,096
|
|
Allogene Therapeutics, Inc. (a)(b)
|
1,556,685
|
15,348,914
|
|
Allovir, Inc. (a)(b)
|
852,383
|
6,401,396
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
1,100,139
|
242,679,662
|
|
ALX Oncology Holdings, Inc. (a)
|
1,280,549
|
14,214,094
|
|
Ambrx Biopharma, Inc. ADR (a)
|
1,361,508
|
667,071
|
|
Amgen, Inc.
|
429,703
|
123,066,939
|
|
Amicus Therapeutics, Inc. (a)(b)
|
2,261,101
|
27,359,322
|
|
AnaptysBio, Inc. (a)(b)
|
273,328
|
7,552,053
|
|
Apellis Pharmaceuticals, Inc. (a)
|
1,431,684
|
71,483,982
|
|
Applied Therapeutics, Inc. (a)(b)(c)
|
2,639,536
|
2,956,280
|
|
Arcellx, Inc.
|
605,400
|
12,071,676
|
|
Arcturus Therapeutics Holdings, Inc. (a)(b)
|
875,824
|
16,150,195
|
|
Arcus Biosciences, Inc. (a)(b)
|
3,193,396
|
112,311,737
|
|
Arcutis Biotherapeutics, Inc. (a)
|
894,174
|
15,406,618
|
|
Argenx SE ADR (a)
|
407,247
|
162,072,089
|
|
Arrowhead Pharmaceuticals, Inc. (a)
|
1,923,532
|
61,937,730
|
|
Ars Pharmaceuticals, Inc. (a)(b)
|
1,675,577
|
10,422,089
|
|
Ascendis Pharma A/S sponsored ADR (a)(b)
|
659,409
|
81,146,872
|
|
aTyr Pharma, Inc. (a)(b)
|
1,146,952
|
2,477,416
|
|
Aura Biosciences, Inc. (a)
|
519,959
|
7,425,015
|
|
Avidity Biosciences, Inc. (a)(b)
|
476,750
|
5,549,370
|
|
Axcella Health, Inc. (a)(b)
|
1,661,354
|
1,396,202
|
|
Beam Therapeutics, Inc. (a)(b)
|
528,692
|
24,420,283
|
|
BELLUS Health, Inc. (a)
|
2,069,064
|
20,421,662
|
|
Bicycle Therapeutics PLC ADR (a)(b)
|
377,647
|
10,936,657
|
|
BioCryst Pharmaceuticals, Inc. (a)(b)
|
3,649,042
|
48,751,201
|
|
Biogen, Inc. (a)
|
703,036
|
214,545,496
|
|
Biohaven Ltd. (a)(b)
|
2,823,752
|
44,671,757
|
|
BioInvent International AB (a)
|
786,506
|
2,700,796
|
|
BioMarin Pharmaceutical, Inc. (a)
|
347,448
|
35,085,299
|
|
Biomea Fusion, Inc. (a)(b)
|
407,129
|
2,927,258
|
|
BioNTech SE ADR
|
185,928
|
31,053,695
|
|
BioXcel Therapeutics, Inc. (a)(b)
|
351,727
|
5,828,116
|
|
Blueprint Medicines Corp. (a)
|
1,461,508
|
69,845,467
|
|
BridgeBio Pharma, Inc. (a)(b)
|
613,842
|
5,751,700
|
|
Candel Therapeutics, Inc. (a)(b)
|
737,596
|
1,290,793
|
|
Celldex Therapeutics, Inc. (a)
|
819,700
|
30,402,673
|
|
Centessa Pharmaceuticals PLC ADR (a)(b)
|
1,230,909
|
4,923,636
|
|
Century Therapeutics, Inc. (a)(b)
|
834,618
|
8,763,489
|
|
Cerevel Therapeutics Holdings (a)(b)
|
1,044,180
|
30,239,453
|
|
Chinook Therapeutics, Inc. (a)
|
303,781
|
6,880,640
|
|
Chinook Therapeutics, Inc. rights (a)(d)
|
115,821
|
1
|
|
Codiak Biosciences, Inc. (a)(b)
|
448,539
|
309,537
|
|
Codiak Biosciences, Inc. warrants 9/15/27 (a)
|
46,000
|
6,217
|
|
Cogent Biosciences, Inc. (a)
|
1,139,767
|
14,338,269
|
|
Compass Therapeutics, Inc.
|
2,232,400
|
9,175,164
|
|
Crinetics Pharmaceuticals, Inc. (a)
|
1,179,587
|
21,079,220
|
|
CRISPR Therapeutics AG (a)(b)
|
305,022
|
16,712,155
|
|
Cyclerion Therapeutics, Inc. (a)
|
837,285
|
795,421
|
|
Cyclerion Therapeutics, Inc. (a)(e)
|
94,809
|
90,069
|
|
Cyteir Therapeutics, Inc. (a)
|
451,123
|
649,617
|
|
Cytokinetics, Inc. (a)(b)
|
2,154,571
|
91,569,268
|
|
Day One Biopharmaceuticals, Inc. (a)
|
845,671
|
17,953,595
|
|
Denali Therapeutics, Inc. (a)
|
417,851
|
13,333,625
|
|
Design Therapeutics, Inc. (a)(b)
|
806,620
|
11,292,680
|
|
Dyne Therapeutics, Inc. (a)
|
310,813
|
3,636,512
|
|
Enanta Pharmaceuticals, Inc. (a)
|
263,946
|
11,558,195
|
|
Entrada Therapeutics, Inc. (a)(b)
|
503,853
|
7,542,679
|
|
EQRx, Inc. (a)
|
507,567
|
1,908,452
|
|
EQRx, Inc.:
|
|||
rights (a)(d)
|
116,649
|
381,442
|
|
rights (a)(d)
|
49,993
|
132,981
|
|
Erasca, Inc. (a)
|
635,623
|
4,798,954
|
|
Evelo Biosciences, Inc. (a)(b)
|
1,098,999
|
2,296,908
|
|
Exelixis, Inc. (a)
|
2,072,034
|
35,390,341
|
|
Fate Therapeutics, Inc. (a)(b)
|
608,787
|
12,674,945
|
|
Foghorn Therapeutics, Inc. (a)(b)
|
252,746
|
1,706,036
|
|
Fusion Pharmaceuticals, Inc. (a)
|
1,142,702
|
2,593,934
|
|
G1 Therapeutics, Inc. (a)
|
276,904
|
1,650,348
|
|
Gemini Therapeutics, Inc. (a)(b)
|
1,555,907
|
2,676,160
|
|
Generation Bio Co. (a)
|
137,100
|
730,743
|
|
Geron Corp. (a)
|
174,306
|
404,390
|
|
Geron Corp. warrants 12/31/25 (a)
|
2,100,000
|
1,396,702
|
|
Gilead Sciences, Inc.
|
437,804
|
38,452,325
|
|
Gossamer Bio, Inc. (a)(b)
|
1,687,174
|
14,442,209
|
|
Graphite Bio, Inc. (a)
|
1,058,457
|
3,736,353
|
|
Gritstone Bio, Inc. (a)(b)
|
431,580
|
1,268,845
|
|
Halozyme Therapeutics, Inc. (a)
|
531,800
|
30,450,868
|
|
Hookipa Pharma, Inc. (a)
|
1,480,200
|
1,569,012
|
|
Horizon Therapeutics PLC (a)
|
325,247
|
32,619,022
|
|
Icosavax, Inc. (a)
|
490,857
|
1,639,462
|
|
Ideaya Biosciences, Inc. (a)(b)
|
715,157
|
12,787,007
|
|
Idorsia Ltd. (a)(b)
|
1,092,661
|
16,200,657
|
|
IGM Biosciences, Inc. (a)(b)
|
591,539
|
13,019,773
|
|
Immuneering Corp. (a)(b)
|
188,677
|
1,224,514
|
|
Immunocore Holdings PLC ADR (a)(b)
|
267,318
|
16,790,244
|
|
ImmunoGen, Inc. (a)
|
922,023
|
4,785,299
|
|
Incyte Corp. (a)
|
427,600
|
34,066,892
|
|
Inhibrx, Inc. (a)(b)
|
254,309
|
7,624,184
|
|
Insmed, Inc. (a)
|
647,392
|
11,970,278
|
|
Instil Bio, Inc. (a)
|
1,445,074
|
1,921,948
|
|
Intellia Therapeutics, Inc. (a)
|
885,001
|
45,542,151
|
|
Ionis Pharmaceuticals, Inc. (a)
|
1,084,277
|
44,227,659
|
|
iTeos Therapeutics, Inc. (a)
|
238,000
|
4,795,700
|
|
Iveric Bio, Inc. (a)
|
555,584
|
13,122,894
|
|
Janux Therapeutics, Inc. (a)(b)
|
714,722
|
9,748,808
|
|
Karuna Therapeutics, Inc. (a)
|
393,512
|
92,597,309
|
|
Keros Therapeutics, Inc. (a)
|
378,977
|
18,888,214
|
|
Kiniksa Pharmaceuticals Ltd. (a)(b)
|
177,166
|
2,981,704
|
|
Kinnate Biopharma, Inc. (a)(b)
|
1,808,291
|
14,321,665
|
|
Kronos Bio, Inc. (a)(b)
|
617,758
|
1,173,740
|
|
Krystal Biotech, Inc. (a)(b)(c)
|
2,105,960
|
163,717,330
|
|
Kymera Therapeutics, Inc. (a)(b)
|
1,072,813
|
31,090,121
|
|
Legend Biotech Corp. ADR (a)
|
912,716
|
47,014,001
|
|
Madrigal Pharmaceuticals, Inc. (a)(b)
|
153,140
|
10,736,645
|
|
MannKind Corp. (a)(b)
|
6,449,301
|
30,182,729
|
|
Merus BV (a)(b)
|
458,686
|
7,040,830
|
|
Mirati Therapeutics, Inc. (a)
|
662,148
|
60,507,084
|
|
Moderna, Inc. (a)
|
888,986
|
156,381,527
|
|
Monte Rosa Therapeutics, Inc. (a)(b)
|
1,257,805
|
10,666,186
|
|
Morphic Holding, Inc. (a)(b)
|
805,337
|
22,162,874
|
|
Morphosys AG sponsored ADR (a)
|
217,028
|
894,155
|
|
Natera, Inc. (a)
|
356,133
|
14,644,189
|
|
Nkarta, Inc. (a)(b)
|
244,766
|
2,075,616
|
|
Nurix Therapeutics, Inc. (a)(b)
|
1,056,746
|
13,093,083
|
|
Nuvalent, Inc. Class A (a)
|
218,574
|
7,186,713
|
|
Omega Therapeutics, Inc. (a)(b)
|
915,541
|
6,408,787
|
|
Oragenics, Inc. (a)
|
155,806
|
30,663
|
|
ORIC Pharmaceuticals, Inc. (a)
|
98,139
|
352,319
|
|
PepGen, Inc.
|
440,591
|
6,591,241
|
|
Poseida Therapeutics, Inc. (a)
|
570,083
|
2,599,578
|
|
Prelude Therapeutics, Inc. (a)
|
359,156
|
2,395,571
|
|
Prometheus Biosciences, Inc. (a)
|
342,555
|
14,082,436
|
|
Protagonist Therapeutics, Inc. (a)
|
124,027
|
981,054
|
|
Prothena Corp. PLC (a)
|
761,589
|
47,606,928
|
|
PTC Therapeutics, Inc. (a)
|
2,267,944
|
94,096,997
|
|
Rallybio Corp. (a)(b)
|
1,550,692
|
8,931,986
|
|
RAPT Therapeutics, Inc. (a)
|
750,682
|
13,272,058
|
|
Recursion Pharmaceuticals, Inc. (a)(b)
|
89,200
|
838,480
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
271,706
|
204,241,400
|
|
Regulus Therapeutics, Inc. (a)(b)(c)
|
2,195,000
|
3,753,450
|
|
Relay Therapeutics, Inc. (a)(b)
|
770,589
|
14,317,544
|
|
Repare Therapeutics, Inc. (a)(b)
|
174,960
|
2,804,609
|
|
Replimune Group, Inc. (a)
|
910,817
|
18,644,424
|
|
Revolution Medicines, Inc. (a)(b)
|
418,772
|
9,878,831
|
|
Rhythm Pharmaceuticals, Inc. (a)(b)
|
826,303
|
22,120,131
|
|
Rocket Pharmaceuticals, Inc. (a)(b)
|
223,736
|
4,224,136
|
|
Roivant Sciences Ltd. (a)(b)
|
5,957,525
|
31,932,334
|
|
Roivant Sciences Ltd. (a)(e)
|
2,500,000
|
13,400,000
|
|
Sage Therapeutics, Inc. (a)
|
699,553
|
28,709,655
|
|
Sarepta Therapeutics, Inc. (a)
|
552,604
|
67,865,297
|
|
Scholar Rock Holding Corp. (a)(b)
|
1,693,925
|
13,161,797
|
|
Scholar Rock Holding Corp. warrants 12/31/25 (a)(e)
|
17,850
|
55,193
|
|
Seagen, Inc. (a)
|
357,732
|
43,425,087
|
|
Selecta Biosciences, Inc. (a)
|
395,568
|
518,194
|
|
Sensorion SA (a)(b)
|
2,243,198
|
992,007
|
|
Seres Therapeutics, Inc. (a)(b)
|
854,347
|
5,553,256
|
|
Shattuck Labs, Inc. (a)
|
110,936
|
251,825
|
|
SpringWorks Therapeutics, Inc. (a)(b)
|
463,711
|
11,212,532
|
|
SpringWorks Therapeutics, Inc. (e)
|
54,800
|
1,192,558
|
|
Stoke Therapeutics, Inc. (a)
|
203,036
|
1,530,891
|
|
Sutro Biopharma, Inc. (a)
|
540,100
|
4,045,349
|
|
Tango Therapeutics, Inc. (a)
|
1,463,188
|
10,988,542
|
|
Taysha Gene Therapies, Inc. (a)
|
811,647
|
1,793,740
|
|
Tenaya Therapeutics, Inc. (a)
|
1,263,918
|
3,349,383
|
|
TG Therapeutics, Inc. (a)(b)
|
1,976,220
|
17,430,260
|
|
Travere Therapeutics, Inc. (a)
|
300,428
|
6,047,616
|
|
Twist Bioscience Corp. (a)(b)
|
681,332
|
18,634,430
|
|
Tyra Biosciences, Inc. (a)
|
342,201
|
2,398,829
|
|
Ultragenyx Pharmaceutical, Inc. (a)
|
978,351
|
35,514,141
|
|
uniQure B.V. (a)
|
255,608
|
6,763,388
|
|
United Therapeutics Corp. (a)
|
442,409
|
123,825,855
|
|
Vaxcyte, Inc. (a)
|
1,355,250
|
62,422,815
|
|
Vera Therapeutics, Inc. (a)
|
779,768
|
13,022,126
|
|
Vertex Pharmaceuticals, Inc. (a)
|
709,810
|
224,583,884
|
|
Verve Therapeutics, Inc. (a)(b)
|
249,393
|
5,793,399
|
|
Vigil Neuroscience, Inc. (b)
|
86,610
|
1,082,625
|
|
Vor Biopharma, Inc. (a)(b)
|
696,659
|
3,204,631
|
|
X4 Pharmaceuticals, Inc. warrants 4/12/24 (a)
|
450,000
|
41
|
|
Xencor, Inc. (a)
|
169,343
|
5,032,874
|
|
Xenon Pharmaceuticals, Inc. (a)
|
1,004,333
|
37,039,801
|
|
Zealand Pharma A/S (a)(b)
|
375,400
|
10,746,405
|
|
Zentalis Pharmaceuticals, Inc. (a)
|
638,433
|
14,122,138
|
|
4,903,853,044
|
|||
Food & Staples Retailing - 0.0%
|
|||
Drug Retail - 0.0%
|
|||
MedAvail Holdings, Inc. (a)
|
2,777
|
1,164
|
|
Health Care Equipment & Supplies - 0.0%
|
|||
Health Care Equipment - 0.0%
|
|||
Alpha Tau Medical Ltd. Class A (a)(b)
|
362,046
|
1,444,564
|
|
Novocure Ltd. (a)
|
11,113
|
853,923
|
|
2,298,487
|
|||
Health Care Providers & Services - 0.2%
|
|||
Health Care Services - 0.2%
|
|||
23andMe Holding Co. Class A (a)(b)
|
2,046,974
|
6,243,271
|
|
Guardant Health, Inc. (a)
|
82,500
|
4,318,050
|
|
10,561,321
|
|||
Health Care Technology - 0.1%
|
|||
Health Care Technology - 0.1%
|
|||
Schrodinger, Inc. (a)
|
199,427
|
3,589,686
|
|
Life Sciences Tools & Services - 0.1%
|
|||
Life Sciences Tools & Services - 0.1%
|
|||
Olink Holding AB ADR (a)
|
57,100
|
1,360,693
|
|
Seer, Inc. (a)
|
304,058
|
1,964,215
|
|
3,324,908
|
|||
Pharmaceuticals - 6.1%
|
|||
Pharmaceuticals - 6.1%
|
|||
Adimab LLC (a)(d)(e)(f)
|
1,954,526
|
78,747,853
|
|
Afferent Pharmaceuticals, Inc. rights 12/31/24 (a)(d)
|
8,274,568
|
8,605,551
|
|
Aradigm Corp. (a)(d)
|
11,945
|
549
|
|
Aradigm Corp. (a)(d)
|
148,009
|
6,808
|
|
Arvinas Holding Co. LLC (a)
|
382,343
|
15,691,357
|
|
Atea Pharmaceuticals, Inc. (a)
|
66,800
|
313,292
|
|
Axsome Therapeutics, Inc. (a)(b)
|
242,373
|
17,521,144
|
|
CinCor Pharma, Inc. (b)
|
81,593
|
962,797
|
|
Corcept Therapeutics, Inc. (a)
|
164,400
|
4,156,032
|
|
DICE Therapeutics, Inc. (a)(b)
|
451,946
|
15,732,240
|
|
Edgewise Therapeutics, Inc. (a)
|
1,704,107
|
15,251,758
|
|
Fulcrum Therapeutics, Inc. (a)(b)
|
1,631,789
|
11,177,755
|
|
GH Research PLC (a)(b)
|
893,124
|
9,770,777
|
|
Harmony Biosciences Holdings, Inc. (a)
|
135,325
|
8,088,375
|
|
Ikena Oncology, Inc. (a)
|
416,547
|
928,900
|
|
Intra-Cellular Therapies, Inc. (a)
|
559,989
|
30,362,604
|
|
Longboard Pharmaceuticals, Inc. (a)
|
371,100
|
1,992,807
|
|
Nuvation Bio, Inc. (a)(b)
|
727,400
|
1,389,334
|
|
OptiNose, Inc. (a)(b)
|
794,031
|
1,405,435
|
|
OptiNose, Inc. warrants (a)
|
91,712
|
59,516
|
|
Pharvaris BV (a)
|
353,507
|
728,224
|
|
Pliant Therapeutics, Inc. (a)(b)
|
372,222
|
6,841,440
|
|
Rain Therapeutics, Inc. (a)
|
206,669
|
1,595,485
|
|
Reata Pharmaceuticals, Inc. (a)(b)
|
381,628
|
15,104,836
|
|
Royalty Pharma PLC
|
285,820
|
12,567,505
|
|
Terns Pharmaceuticals, Inc. (a)
|
810,600
|
6,298,362
|
|
Theseus Pharmaceuticals, Inc. (a)(b)
|
1,857,891
|
12,243,502
|
|
Trevi Therapeutics, Inc. (a)
|
1,299,855
|
2,443,727
|
|
UCB SA
|
121,277
|
9,789,060
|
|
Ventyx Biosciences, Inc. (a)(b)
|
716,630
|
20,775,104
|
|
Verona Pharma PLC ADR (a)
|
290,000
|
3,741,000
|
|
Verrica Pharmaceuticals, Inc. (a)(b)
|
1,597,876
|
5,193,097
|
|
WAVE Life Sciences (a)(b)
|
1,696,733
|
7,194,148
|
|
326,680,374
|
|||
|
TOTAL COMMON STOCKS
(Cost $3,973,997,054)
|
5,250,308,984
|
||
Convertible Preferred Stocks - 1.4%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 1.2%
|
|||
Biotechnology - 1.2%
|
|||
ElevateBio LLC Series C (a)(d)(e)
|
216,600
|
990,512
|
|
Korro Bio, Inc.:
|
|||
Series B1 (d)(e)
|
957,854
|
1,829,501
|
|
Series B2 (d)(e)
|
899,280
|
1,717,625
|
|
National Resilience, Inc. Series B (a)(d)(e)
|
732,064
|
44,458,247
|
|
SalioGen Therapeutics, Inc. Series B (d)(e)
|
94,461
|
7,043,957
|
|
ValenzaBio, Inc. Series A (a)(d)(e)
|
1,685,311
|
9,993,894
|
|
66,033,736
|
|||
Health Care Providers & Services - 0.1%
|
|||
Health Care Services - 0.1%
|
|||
Scorpion Therapeutics, Inc. Series B (a)(d)(e)
|
3,099,905
|
3,874,881
|
|
Pharmaceuticals - 0.1%
|
|||
Pharmaceuticals - 0.1%
|
|||
Afferent Pharmaceuticals, Inc. Series C (a)(d)(e)
|
8,274,568
|
83
|
|
Aristea Therapeutics, Inc. Series B (a)(d)(e)
|
836,400
|
6,431,916
|
|
6,431,999
|
|||
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $53,020,299)
|
76,340,616
|
||
Money Market Funds - 8.5%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 3.86% (g)
|
9,911,593
|
9,913,575
|
|
Fidelity Securities Lending Cash Central Fund 3.86% (g)(h)
|
447,029,121
|
447,073,824
|
|
|
TOTAL MONEY MARKET FUNDS
(Cost $456,953,758)
|
456,987,399
|
||
|
TOTAL INVESTMENT IN SECURITIES - 108.1%
(Cost $4,483,971,111)
|
5,783,636,999
|
NET OTHER ASSETS (LIABILITIES) - (8.1)%
|
(435,779,983)
|
NET ASSETS - 100.0%
|
5,347,857,016
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Affiliated company
|
(d)
|
Level 3 security
|
(e)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $169,826,289 or 3.2% of net assets.
|
(f)
|
Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
|
(g)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(h)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Adimab LLC
|
9/17/14 - 6/05/15
|
31,218,977
|
Afferent Pharmaceuticals, Inc. Series C
|
7/01/15
|
0
|
Aristea Therapeutics, Inc. Series B
|
10/06/20
|
4,611,659
|
Cyclerion Therapeutics, Inc.
|
4/02/19
|
1,404,026
|
ElevateBio LLC Series C
|
3/09/21
|
908,637
|
Korro Bio, Inc. Series B1
|
12/17/21
|
2,499,999
|
Korro Bio, Inc. Series B2
|
12/17/21
|
2,499,998
|
National Resilience, Inc. Series B
|
12/01/20
|
9,999,994
|
Roivant Sciences Ltd.
|
5/01/21
|
25,000,000
|
SalioGen Therapeutics, Inc. Series B
|
12/10/21
|
10,000,019
|
Scholar Rock Holding Corp. warrants 12/31/25
|
6/17/22
|
0
|
Scorpion Therapeutics, Inc. Series B
|
1/08/21
|
7,500,000
|
SpringWorks Therapeutics, Inc.
|
9/07/22
|
1,425,348
|
ValenzaBio, Inc. Series A
|
3/25/21
|
14,999,993
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 3.86%
|
42,446,755
|
853,872,649
|
886,405,829
|
410,199
|
3,258
|
(3,258)
|
9,913,575
|
0.0%
|
Fidelity Securities Lending Cash Central Fund 3.86%
|
492,109,261
|
1,822,937,237
|
1,867,972,674
|
6,001,517
|
-
|
-
|
447,073,824
|
1.4%
|
Total
|
534,556,016
|
2,676,809,886
|
2,754,378,503
|
6,411,716
|
3,258
|
(3,258)
|
456,987,399
|
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
Adverum Biotechnologies, Inc.
|
-
|
14,311,389
|
1,586,381
|
-
|
(1,487,269)
|
(5,655,743)
|
5,581,996
|
Applied Therapeutics, Inc.
|
1,070,923
|
2,575,660
|
1,176,547
|
-
|
(14,439,872)
|
14,926,116
|
2,956,280
|
Candel Therapeutics, Inc.
|
8,593,545
|
-
|
6,141,156
|
-
|
(4,644,572)
|
3,482,976
|
-
|
Krystal Biotech, Inc.
|
126,760,516
|
6,531,325
|
-
|
-
|
-
|
30,425,489
|
163,717,330
|
Regulus Therapeutics, Inc.
|
-
|
4,631,450
|
-
|
-
|
-
|
(878,000)
|
3,753,450
|
Total
|
136,424,984
|
28,049,824
|
8,904,084
|
-
|
(20,571,713)
|
42,300,838
|
176,009,056
|